Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 213-222

  Kelin, Katarina ^a   Lambert, Timothy J R ^b   Brnabic, Alan J M ^a   Newton, Richard ^c,h   Ye, Wendy ^a   Escamilla, Raúl I ^d   Chen, Kuang Peng ^e   Don, Liana ^f   Montgomery, William ^a   Karagianis, Jamie ^g   Ascher Svanum, Haya ^g  

^a ELI LILLY AUSTRALIA PTY LTD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c FRANKSTON HOSPITAL   (Australia)

^d INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f University of Medicine Iuliu Hatieganu Cluj Napoca   (Romania)

^g ELI LILLY AND COMPANY   (United States)

^h AUSTIN HOSPITAL   (Australia)

Author keywords

Antipsychotic drugs; Depot antipsychotic; Medication persistence; Nonadherence; Outpatients; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PIPOTIAZINE PALMITATE; RISPERIDONE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL DECANOATE;

ADULT; AGED; ARTICLE; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; QUALITY OF LIFE; SCHIZOPHRENIA; SELF CONCEPT; TREATMENT RESPONSE;

EID: 84855354711     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S16800     Document Type: Article

References (44)

1. Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry. 2005;50(Suppl 1):7-57.
2. Haro JM, Novick D, Suarez D, Roca M. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. J Psychiatr Res. 2009;43: 265-273.
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
4. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care. 2002;40:630-639.
5. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886-891.
6. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52:805-811.
7. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:21.
8. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006;6:8.
9. Dunayevich E, Ascher-Svanum H, Zhao F, et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 2007;68:1163-1171.
10. Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry. 1990;41:1203-1211.
11. Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry. 2009;11:147-154.
12. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29:15-31.
13. Chen L, McCombs JS, Park J. Duration of antipsychotic drug therapy in real-world practice: a comparison with CATIE trial results. Value Health. 2008;11:487-496.
14. Haro JM, Novick D, Belger M, Jones PB. Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur Psychiatry. 2006;21:41-47.
15. Kilzieh N, Todd-Stenberg JA, Kennedy A, Wood AE, Tapp AM. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting. J Clin Psychopharmacol. 2008;28:74-77.
16. Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res. 2008;98:8-15.
17. Ascher-Svanum H, Zhu B, Faries DE, Lacro JP, Dolder CR, Peng X. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence. 2008;2:67-77.
18. Dossenbach M, Arango-Dávila C, Silva Ibarra H, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry. 2005;66:1021-1030.
19. Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry. 2006;67: 1114-1123.
20. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892-909.
21. Kelin K, Brnabic AJM, Newton R, et al. Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence. Pat Pref Adherence. 2010;4:301-311.
22. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-IV). Washington DC: American Psychiatric Association; 1994.
23. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
24. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183.
25. The EuroQol Group: EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
26. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
27. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-1108.
28. Karagianis J, Williams R, Davis L, et al. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia. Curr Med Res Opin. 2009;25:2121-2132.
29. Serretti A, De Ronchi D, Lorenzi C, Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem. 2004;11:343-358.
30. Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333:224.
31. Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv. 2008;59:315-317.
32. Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007; 22:275-282.
33. Patel MX, de Zoysa N, Bernadt M, David AS. A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral. J Clin Psychiatry. 2008;69:1548-1556.
34. Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry. 2006;67: 1948-1953.
35. Hamann J, Mendel R, Heres S, Leucht S, Kissling W. How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed? Eur Neuropsychopharmacol. 2010; 20:276-279.
36. Chong MY, Tan CH, Fujii S, et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci. 2004;58:61-67.
37. Yang YK, Tarn YH, Wang TY, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin Neurosci. 2005;59:385-394.
38. Weiden PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry. 2007;68(Suppl 14): 14-19.
39. Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32:724-742.
40. Barbui C, Kikkert M, Mazzi MA, et al. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology. 2009;42:311-317.
41. Cooper D, Moisan J, Grégoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry. 2007;68:818-825.
42. Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005;133:129-133.
43. Nosé M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med. 2003;33:1149-1160.
44. Bitter I, Treuer T, Dyachkova Y, Martenyi F, McBride M, Ungvari GS. Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Neuropsychopharmacol. 2008;18: 170-180.